Endpoints News 生物医药· Ryan Cross·· 2 天前AI 评分49
CTAD26:Biogen tau靶向药近两年用药后延缓阿尔茨海默病进展更显著
#CTAD26: Biogen’s tau drug slows Alzheimer’s more after nearly two years
AI 导读
在CTAD26会议上,Biogen报告其实验性阿尔茨海默病tau药物的数据似乎随用药时间延长而改善,最低剂量组的初步结果显示更长病程中疾病进展进一步减缓。
正文
BOSTON — The benefits of Biogen’s experimental Alzheimer’s drug seem to get better with time.
Over the summer, Biogen reported that the lowest dose of its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news